Author:
Ou Sai-Hong Ignatius,Bazhenova Lyudmila,Camidge D. Ross,Solomon Benjamin J.,Herman June,Kain Tatiana,Bang Yung-Jue,Kwak Eunice L.,Shaw Alice T.,Salgia Ravi,Maki Robert G.,Clark Jeffrey W.,Wilner Keith D.,Iafrate A. John
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference7 articles.
1. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009
2. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010
3. The biology and treatment of EML4-ALK non-small cell lung cancer;Sasaki;Eur J Cancer,2010
4. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of nonsmall cell lung cancer;Solomon;J Thorac Oncol,2009
5. Solomon B, Bang Y, Camidge DR, et al. Timing of response to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC). 22nd EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics, Berlin, Germany. Abstract 369.
Cited by
79 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献